Group 1 - The company Jinhe Biological announced that as of the disclosure date, the total external guarantee balance of the company and its subsidiaries is approximately 673 million yuan, which includes the expected new guarantee and excludes the subsidiary's guarantee to the company of 460 million yuan, accounting for 29.95% of the company's audited net assets attributable to the parent company for 2024 [1] - The expected new guarantee amount is approximately 121 million yuan, which accounts for 5.37% of the company's audited net assets attributable to the parent company for 2024 [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reportedly busy with orders scheduled until 2028, operating in three shifts and maintaining 24-hour production lines [1]

Core Viewpoint - The animal health sector experienced a decline of 2.02% on January 29, with Zhongmu Co., Ltd. leading the losses. The Shanghai Composite Index rose by 0.16%, while the Shenzhen Component Index fell by 0.3. [1] Group 1: Market Performance - The closing price of Zhongmu Co., Ltd. was 8.11, down 4.92%, with a trading volume of 416,400 shares and a transaction value of 341 million yuan [2] - The animal health sector saw a net outflow of 111 million yuan from main funds, while retail investors had a net inflow of 48.56 million yuan [2][3] Group 2: Individual Stock Performance - Xianfeng Holdings closed at 4.03, up 1.26%, with a trading volume of 406,400 shares and a transaction value of 161 million yuan [1] - The stock of Jinhai Biological fell by 1.32% to 6.71, with a trading volume of 272,000 shares and a transaction value of 183 million yuan [1] - The stock of Ruipu Biological decreased by 1.34% to 19.95, with a trading volume of 84,500 shares and a transaction value of 169 million yuan [1] Group 3: Fund Flow Analysis - Jinhai Biological had a main fund net inflow of 10.3 million yuan, while retail investors had a net outflow of 5.3 million yuan [3] - Zhongmu Co., Ltd. saw a main fund net inflow of 6.23 million yuan, but a retail net outflow of 32.7 million yuan [3] - The stock of Shunlian Biological experienced a significant main fund net outflow of 8.9 million yuan, with retail investors having a net inflow of 5.6 million yuan [3]

Group 1 - The company, Zhongmu Co., Ltd., expects to achieve a net profit attributable to shareholders of approximately 149 million to 192 million yuan for the year 2025, representing an increase of 77.7037 million to 121 million yuan compared to the previous year, which corresponds to a year-on-year growth of 109.62% to 171.27% [1] - The significant change in performance is primarily attributed to the company's subscription of convertible bonds issued by Xiamen Jindawei Group Co., Ltd., and the decision to waive the preferential purchase rights for shares of Zhongpu Biopharmaceutical Co., Ltd., leading to substantial increases in fair value change gains and investment income [1] Group 2 - The industry is witnessing a pivotal year for power battery technology, with semi-solid batteries expected to be equipped in multiple new vehicles this year, as major manufacturers prepare for advancements in battery technology [1]

Core Viewpoint - Zhongmu Co., Ltd. (600195.SH) forecasts a significant increase in net profit for the year 2025, projecting a range of CNY 148.59 million to CNY 192.29 million, representing a year-on-year increase of CNY 77.70 million to CNY 121.41 million, or a growth of 109.62% to 171.27% [1] Group 1 - The company expects to achieve a net profit attributable to shareholders of CNY 148.59 million to CNY 192.29 million for the year 2025 [1] - This projected profit increase is attributed to a substantial rise in fair value changes and investment income, following the company's decision to subscribe to convertible bonds issued by Xiamen Jindawei Group Co., Ltd. and to waive the preferential purchase rights for shares in Zhongpu Biopharmaceutical Co., Ltd. [1] - The anticipated increase in net profit is a result of both operational performance and strategic investment decisions made by the company [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

2025年，公司认购厦门金达威集团股份有限公司发行的可转换公司债券，同时放弃中普生物制药有限公 司股权的优先购买权，公允价值变动收益和投资收益同比大幅增加，因此，2025年度归属于上市公司股 东的净利润同比增加。2025年，公司积极应对多重压力，及时优化营销结构，深挖客户需求，积极开发 新产品、拓展新业务；同时公司也进一步加强对日常运营的统筹管理，努力推进公司整体的降本增效。 目前，公司产品市场占有率仍保持较大韧性和活力，公司生产经营平稳有序。 格隆汇1月28日丨中牧股份(600195.SH)公布，预计2025年度实现归属于上市公司股东的净利润14,858.81 万元到19,229.05万元，同比增加109.62%到171.27%。预计2025年度归属于上市公司股东的扣除非经常 性损益的净利润1,690.01万元到2,323.76万元,同比减少62.60%到72.80%。 ...

中牧股份公告称，预计2025年度实现归属于上市公司股东的净利润14,858.81万元到19,229.05万元，同比 增加109.62%到171.27%；扣非净利润1,690.01万元到2,323.76万元，同比减少62.60%到72.80%。2024年 净利润为7,088.44万元。业绩预增主因是认购可转换公司债券、放弃优先购买权致公允价值变动收益和 投资收益同比大增。数据未经审计，具体以年报为准。 ...

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Group 1 - The core viewpoint of the news is that Reap Bio has seen a 5% increase in stock price, reaching 21.40 CNY per share, with a trading volume of 221 million CNY and a turnover rate of 3.17%, resulting in a total market capitalization of 9.946 billion CNY [1] - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in the research, production, sales, and technical services of veterinary biological products, chemical drugs, biological agents, and other related products [1] - The main business revenue composition of Reap Bio is 77.95% from animal protection business and 22.05% from the pet supply chain [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 2.3571 million shares, totaling 6.3383 million shares, which accounts for 1.89% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF has a current scale of 5.949 billion CNY, with a year-to-date loss of 0.41% and a one-year return of 15.98% [2] - The fund manager of Guotai Zhongzheng Animal Husbandry ETF, Liang Xing, has a tenure of 9 years and 235 days, with the fund's total asset size at 29.35 billion CNY and a best return of 1112.34% during the tenure [3]